BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20504250)

  • 1. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
    Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
    Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
    Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
    Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F
    Oncology; 2013; 84(4):191-9. PubMed ID: 23328390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
    Terrazzino S; Agostini M; Pucciarelli S; Pasetto LM; Friso ML; Ambrosi A; Lisi V; Leon A; Lise M; Nitti D
    Pharmacogenet Genomics; 2006 Nov; 16(11):817-24. PubMed ID: 17047490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma].
    Garajová I; Svoboda M; Slabý O; Kocáková I; Fabian P; Kocák I; Vyzula R
    Klin Onkol; 2008; 21(6):330-7. PubMed ID: 19382596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy.
    Kim JS; Kim JM; Li S; Yoon WH; Song KS; Kim KH; Yeo SG; Nam JS; Cho MJ
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):195-200. PubMed ID: 16839708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
    Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
    J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
    Cecchin E; Agostini M; Pucciarelli S; De Paoli A; Canzonieri V; Sigon R; De Mattia E; Friso ML; Biason P; Visentin M; Nitti D; Toffoli G
    Pharmacogenomics J; 2011 Jun; 11(3):214-26. PubMed ID: 20368715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
    Spindler KL; Nielsen JN; Lindebjerg J; Jakobsen A
    Dis Colon Rectum; 2007 Sep; 50(9):1363-9. PubMed ID: 17661145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment.
    Soumarova R; Skrovina M; Bartos J; Gruna J; Wendrinski A; Czudek S; Kycina R; Parvez J
    Eur J Surg Oncol; 2010 Mar; 36(3):251-6. PubMed ID: 19879716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.
    Páez D; Paré L; Altés A; Sancho-Poch FJ; Petriz L; Garriga J; Monill JM; Salazar J; del Rio E; Barnadas A; Marcuello E; Baiget M
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1681-9. PubMed ID: 20165956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.